Bone Scan in a Patient with Prostate Cancer and New Back Pain
A 70-year-old man with Gleason 8 prostate cancer, status post radical prostatectomy 3 years ago, presents with 6 weeks of progressive low back pain radiating to the left leg. PSA is 0.4 ng/mL (previously undetectable). He has no focal neurologic deficits but reports numbness in the left L5 distribution. A whole-body bone scan is ordered. The scan shows increased uptake in the left sacroiliac region and a questionable focus in the L4 vertebral body. He also has known degenerative disc disease and a history of a left total hip arthroplasty 10 years ago.
1. How should the bone scan findings be interpreted given the PSA and the history of hip arthroplasty, and what is the appropriate next step?
Read the worked answer
The bone scan is nonspecific: increased uptake in the left sacroiliac region and L4 could represent metastatic disease, but the sacroiliac uptake may reflect degenerative change or altered mechanics from the left hip arthroplasty, and L4 could be degenerative. A PSA of 0.4 ng/mL is low but not undetectable, and a rising PSA after prostatectomy is a more sensitive marker of recurrence than bone scan. The appropriate next step is correlation with cross-sectional imaging (MRI of the lumbar spine and pelvis, or CT) to characterize the L4 lesion and assess for cord or nerve root compromise, given the radicular symptoms and numbness. If MRI is contraindicated, CT myelography or PET (e.g., PSMA PET) may be considered. The judgment is that a single bone scan in a patient with low PSA and confounding orthopedic history should not drive treatment decisions without anatomic confirmation.
2. If MRI confirms a solitary L4 metastasis with epidural extension and the patient has no prior systemic therapy for metastatic disease, how does this change the imaging and treatment plan?
Read the worked answer
A solitary L4 metastasis with epidural extension is an oncologic urgency because of potential cord compression, so the immediate priority is neurosurgical/radiation oncology consultation and steroids if cord compromise is threatened, regardless of PSA. For staging, PSMA PET/CT is now preferred over conventional bone scan and CT in biochemically recurrent or oligometastatic prostate cancer because it detects small nodal and osseous disease that bone scan misses, and it would clarify whether this is truly solitary. Treatment would shift from local therapy alone to systemic therapy (androgen deprivation with or without novel hormonal agents or chemotherapy depending on risk) plus local radiation or surgery for the L4 lesion. The bone scan's limited sensitivity in low-PSA disease and its inability to distinguish degenerative from metastatic uptake are the reasons it should not be the sole staging modality here.